SynthesisFrontiers in medicine2025
Best evidence summary for the management of epidermal growth factor receptor inhibitor-induced skin toxicity symptoms in cancer patients.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Patient perspectives on epidermal growth factor receptor inhibitor-induced skin toxicities: a qualitative study.Frontiers in psychology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to evaluate and summarize the best available evidence on the management of epidermal growth factor receptor inhibitor-induced skin toxicity symptoms in cancer patients, serving as a reference for medical staff. Methods: We systematically searched for evidence on skin toxicity symptoms in databases such as China National Knowledge Infrastructure (CNKI) and Wanfang; guideline repositories such as Guidelines International Network (GIN) and New Zealand Guidelines Group (NZGG); and professional organization websites such as International Union Against Cancer (UICC) and American Cancer Society (ACS). The search time was limited from database establishment to July 2024. Two researchers evaluated the quality of the literature and extracted the data. Results: A total of 20 articles were included in this study, including 3 clinical decisions, 7 guidelines, 3 evidence summaries, 2 recommended practices, and 5 expert consensuses. Finally, 27 pieces of evidence were identified across 9 aspects: professional medical training, patient health education, precise skin assessment, reducing skin irritation, promoting skin comfort, skin sun protection care, skin moisturizing care, drug preventive measures, and drug treatment measures. Conclusion: Our research summarizes the best evidence for the management of epidermal growth factor receptor inhibitors (EGFRI)-induced skin toxicity symptoms in cancer patients. In clinical practice, it is necessary to fully consider the clinical situation, balance professional judgment with patients' preferences, follow the principle of individualization, analyze the obstacles and facilitating factors of the application of evidence, and apply the evidence to clinical practice prudently.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.